Market Overview

Barclays Analyst Pens Open Letter To Gilead Board And Management

Barclays Analyst Pens Open Letter To Gilead Board And Management
Related GILD
New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Senate Dems introduce bill to block "excessive" increases in drug prices (Seeking Alpha)

On Friday, Barclays analyst Geoff Meacham veered from his typical approach of addressing clients and chose to speak directly to management at Gilead Sciences, Inc. (NASDAQ: GILD). Meacham chose to structure his latest research note on the pharma giant as a letter to the company, which included five recommendations for ways the company could potentially boost its market valuation.

According to Meacham, market sentiment toward Gilead seems to be at a low point recently.

“The purpose of this letter isn’t to single out your company as one that has been mismanaged (it hasn’t); rather, it is to provide context for the current valuation and with five concluding recommendations, help carve a roadmap to a re-rating,” Meacham explained.

5-Step Process

Barclays believes Gilead management can be proactive by taking the following five steps:

    1. Consider transformational M&A deals outside of the company’s core businesses.
    2. Consider cutting costs in the hepatitis C business if the market continues to decline.
    3. Give more clarity on the potential impact of the HIV franchise by providing guidance.
    4. Consider taking a more aggressive approach to in-licensing/business development.
    5. Consider shifting focus away from capital return and more toward reinvesting in the business via M&A and other potential growth measures.

Like most pharma stocks, Gilead has had a rough go of it in the past year, with shares now down 21.9 percent.

Barclays remains optimistic, however. The firm maintains an Outperform rating and a $90 price target for the stock.

Related Link:

  • Here's Who's Getting A Tax Cut Under The New Healthcare Proposal (You're Probably Not Included)
  • Response To GOP Healthcare Bill Ranges From Tepid Support To Outright Opposition
  • Latest Ratings for GILD

    Oct 2018Raymond JamesMaintainsStrong BuyStrong Buy
    Oct 2018Cantor FitzgeraldMaintainsOverweightOverweight
    Oct 2018PiperJaffrayDowngradesOverweightNeutral

    View More Analyst Ratings for GILD
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Politics Analyst Ratings Movers Trading Ideas Best of Benzinga


    Related Articles (GILD)

    View Comments and Join the Discussion!

    Latest Ratings

    SYBXChardan CapitalInitiates Coverage On20.0
    GEJP MorganUpgrades6.0
    FEYEMorgan StanleyDowngrades21.0
    View the Latest Analytics Ratings
    Don't Miss Out!
    Join Our Newsletter
    Subscribe to:
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Daily Analyst Rating
    A summary of each day’s top rating changes from sell-side analysts on the street.
    Fintech Focus
    Your weekly roundup of hot topics in the exciting world of fintech.
    Thank You
    for registering for Benzinga’s newsletters and alerts.
    • The Daily Analysts Ratings email will be received daily between 7am and 10am.
    • The Market in 5 Minutes email will be received daily between 7am and 8am.
    • The Fintech Focus email will be received every Friday between 2pm and 5pm.

    A Day In The Life Of The Fintech CEO Attacking Student Loan Debt

    Ulta Reported 'Another Monster Quarter,' But Guidance Was Conservative